Sustainable Growth Advisers LP Sells 84,403 Shares of Danaher Corporation $DHR

Sustainable Growth Advisers LP reduced its position in shares of Danaher Corporation (NYSE:DHR) by 3.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,438,553 shares of the conglomerate’s stock after selling 84,403 shares during the period. Danaher accounts for about 2.5% of Sustainable Growth Advisers LP’s holdings, making the stock its 18th biggest position. Sustainable Growth Advisers LP owned approximately 0.34% of Danaher worth $481,712,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. MGO One Seven LLC lifted its stake in Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after purchasing an additional 20,813 shares in the last quarter. Chicago Capital LLC boosted its stake in Danaher by 11.6% during the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares during the period. UniSuper Management Pty Ltd raised its position in shares of Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after buying an additional 2,667 shares in the last quarter. Nvwm LLC raised its stake in shares of Danaher by 20.4% during the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after acquiring an additional 1,204 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. lifted its holdings in shares of Danaher by 1.9% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after acquiring an additional 6,136 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $221.25 on Friday. The company’s fifty day moving average price is $205.63 and its 200-day moving average price is $201.09. The stock has a market cap of $156.28 billion, a PE ratio of 45.62, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm posted $1.71 earnings per share. Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is 26.39%.

Analyst Ratings Changes

Several research firms have weighed in on DHR. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Cowen restated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Bank of America lowered their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a report on Tuesday, September 2nd. Finally, Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 10th. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $243.39.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 29,728 shares of company stock worth $6,448,990. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.